Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | NTRK1 fusion |
| Therapy | Larotrectinib |
| Indication/Tumor Type | central nervous system cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| NTRK1 fusion | central nervous system cancer | sensitive | Larotrectinib | Phase II | Actionable | In two Phase II trials, Vitrakvi (larotrectinib) treatment resulted in an objective response rate of 30% (10/33, 3 complete responses, 7 partial responses) in pediatric and adult patients with primary central nervous system tumors harboring NTRK fusions including high grade (n=19) and low grade (n=8) gliomas, with a 24-week disease control rate of 73% and a 12-month progression-free survival rate of 56% (PMID: 34850167; NCT02637687, NCT02576431). | 34850167 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (34850167) | Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors. | Full reference... |